Cover Story
FreeGuest Editorial
The recent FDA approvals of a cell/gene therapy for patients with advanced B cell malignancies provide a glimpse into a paradigm shift in the treatment of hematologic and solid cancers, the creation of a new drug unique to each cancer patient.
In Brief
Clinical Roundup
Drugs & Targets
NCI Trials
NCI CTEP-Approved Trials for January
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
